Objective:To explore the application value of Jiedu Jiangtang Futan Decoction combined with acupuncture and moxibustion in the treatment of acute cerebral infarction patients with diabetes(qi deficiency and blood stasis type).Methods:All pa-tients with acute cerebral infarction complicated with diabetes(type of qi deficiency and blood stasis)were treated in Hongdu Tradi-tional Chinese Medicine Hospital from October 2020 to September 2022 and randomly divided into two groups,with 69 cases in each group.The control group was treated with conventional western medicine,and the observation group was treated with Jiedu Jiangtang Futan Decoction and acupuncture and moxibustion,and the efficacy was compared after two weeks of treatment.Results:Compared with before treatment,the serum levels of superoxide dismutase(SOD),vascular endothelial growth factor(VEGF)and brain-derived neurotrophic factor(BDNF)were increased in the two groups after treatment.The levels of serum matrix metalloproteinase-9(MMP-9),IL-6,fasting blood glucose(FBG),2-hour postprandial glucose(2 h PG)and glycated hemoglobin(HbA1c)were decreased.The Barthel index(BI)was increased,and the modified Rankin score(mRS)and National Institutes of Health Stroke Scale(NIHSS)were decreased(P<0.05).Compared with the control group,the levels of SOD,VEGF,BDNF and other indicators in the observation group were higher after treatment.The levels of MMP-9,IL-6,FBG,2 h PG and HbA1c were lower.BI was higher,mRS and NIHSS were lower,the difference were statistically significant(P<0.05).The total effective rate in the observation group was 94.20%(65/69),higher than 84.06%(58/69)in the control group(P<0.05).Conclusion:For patients with acute cerebral infarction complicated with diabetes(type of qi deficiency and blood stasis),the combination of Jiedu Jiangtang Futan Decoction and acupuncture and moxi-bustion treatment is helpful to promote blood supply to the brain,correct the imbalance of oxidative stress,regulate blood sugar level and improve clinical efficacy.

Objective To explore the application value of Kaiqiao Xingshen acupuncture combined with Buyang Huanwu decoction in the treatment of patients with cerebral hemorrhage in the recovery period(Qi defi-ciency and blood stasis syndrome),and to observe its impact on inflammatory indicators and neurokines.Method A total of 166 patients with cerebral hemorrhage in the recovery period(Qi deficiency and blood stasis syndrome)treated in Hongdu Traditional Chinese Medicine Hospital from September 2021 to October 2023,were randomly divided into control group(83 cases treated with conventional western medicine),and observation group(83 cases treated with a combination of Kaiqiao Xingshen acupuncture and Buyang Huanwu decoction).The therapeutic effect in the two groups was compared after 8 weeks of treatment.Results After treatment,the serum levels of matrix metalloproteinase-9(MMP-9),endothelin-1(ET-1),interleukin-2(IL-2),homocysteine(Hcy),and Bcl-2-associated X protein(bax)decreased in both groups,while brain-derived neurotrophic factor(BDNF)increased,and the improvement was more significant in the observation group,showing statistical significance(P<0.05);the average cerebral vascular flow and flow velocity in the observation group increased,while peripheral vascular resistance decreased,and the improvement in the observation group was more significant(P<0.05);the total symptom score of traditional Chinese medicine in the observation group decreased,while the Fuel Meyer functional score(FMA score)increased,and the improvement in the observation group was more significant(P<0.05);The total effective rate of the observation group was 93.98%(78/83),which was higher than that of the control group(80.72%,67/83)(P<0.05).Conclusion For patients with cerebral hemorrhage in the recovery period(Qi deficiency and blood stasis syndrome),Kaiqiao Xingshen acupuncture and Buyang Huanwu decoction help alleviate inflammatory reactions,promote the recovery of the blood-brain barrier,improve cerebral blood flow,promote neurological function recovery,and enhance clinical efficacy.

Objective:To evaluate the efficacy and safety of nebulized inhalation of recombinant human interferon (IFN) α1b injection in the treatment of respiratory syncytial virus (RSV) associated lower respiratory tract infections (pneumonia and bronchiolitis) in children.Methods:A randomized, double-blind, parallel, placebo-controlled add-on design was used.Children with pneumonia or bronchiolitis aged 2 months to 5 years who tested positive for RSV antigen within 72 hours of onset from 30 clinical trial sites including Beijing Children′s Hospital, Capital Medical University between February 2021 and December 2022 were included in this study and randomly divided into 2 groups at a ratio of 1∶1 based on a stratified-block method.Both groups received basic treatments such as cough control, asthma relieving, expectorant treatment, fever reduction, oxygen therapy, etc.The experimental group received additional nebulized inhalation of IFN α1b injection at a dose of 2.0 μg/(kg·time), twice a day.The control group received nebulized inhalation of placebo twice a day.Clinical efficacy was evaluated based on indicators such as the duration of clinical symptoms and signs, and the Kaplan-Meier method was used to calculate the median and 95% CI of the duration of clinical symptoms and signs.The Log-rank test was used to compared data between groups.Safety was assessed through the incidence of adverse reactions and laboratory tests, and the Chi-square test was used to analyze the difference between groups. Results:There were 123 children in the experimental group and 122 children in the control group.The median durations of all the 5 clinical symptoms and signs [including shortness of breath, wheezing, dyspnea (visible retractions), decreased transcutaneous oxygen saturation, and abnormal mental state] in the experimental group after treatment were slightly shortened than those in the control group [2.7 d(95% CI: 1.9-3.0 d)] vs.[2.9 d(95% CI: 2.6-3.6 d), P=0.027].The improvement in dyspnea (retractions) was especially pronounced in the experimental group, with a relief rate of 50.0% (0, 100%) on the first day of administration[compared with 0 (0, 50.0%) in the control group ( Z=2.002, P=0.025)].The median duration of dyspnea in the experimental group was nearly 1 day shorter than that in the control group [1.0 d(95% CI: 0.7-1.7 d) vs.1.8 d(95% CI: 1.0-2.5 d), P=0.046].There were no significant difference in hospital stay [6.0(5.0, 8.0) d vs.6.5(5.0, 8.0) d, Z=0.675, P=0.500], oxygen therapy duration [32.0(14.0, 96.3) h vs.39.0 (24.0, 83.2) h, Z=0.094, P=0.925], the recovery rate from clinical symptoms during treatment [(105/106, 99.1%) vs.(96/101, 95.0%)], and recurrence rate [(0/106, 0) vs.(2/101, 2.0%)] between the 2 groups (all P>0.05).However, the above-mentioned four indicators in the experimental group showed a trend of clinical benefits.The quantitative virus detection results showed that the RSV viral load in both groups decreased after treatment compared to before treatment.After 2 days of treatment, the decline rate of RSV viral load from the baseline was 0.90 lg copies/(mL·d) in the experimental group and 0.25 lg copies/(mL·d)in the control group, with a statistically significant difference ( P<0.05).Furthermore, there was no statistically significant difference in the incidence of adverse reactions between the 2 groups ( P>0.05).Importantly, no drug-related serious adverse reactions occurred in both groups. Conclusions:The nebulized inhalation therapy of IFN α1b demonstrates efficacy and safety in treating pediatric RSV associated lower respiratory tract infections.It particularly offers outstanding clinical therapeutic value for severe children.

Objective:To explore the application value of Jiedu Jiangtang Futan Decoction combined with acupuncture and moxibustion in the treatment of acute cerebral infarction patients with diabetes(qi deficiency and blood stasis type).Methods:All pa-tients with acute cerebral infarction complicated with diabetes(type of qi deficiency and blood stasis)were treated in Hongdu Tradi-tional Chinese Medicine Hospital from October 2020 to September 2022 and randomly divided into two groups,with 69 cases in each group.The control group was treated with conventional western medicine,and the observation group was treated with Jiedu Jiangtang Futan Decoction and acupuncture and moxibustion,and the efficacy was compared after two weeks of treatment.Results:Compared with before treatment,the serum levels of superoxide dismutase(SOD),vascular endothelial growth factor(VEGF)and brain-derived neurotrophic factor(BDNF)were increased in the two groups after treatment.The levels of serum matrix metalloproteinase-9(MMP-9),IL-6,fasting blood glucose(FBG),2-hour postprandial glucose(2 h PG)and glycated hemoglobin(HbA1c)were decreased.The Barthel index(BI)was increased,and the modified Rankin score(mRS)and National Institutes of Health Stroke Scale(NIHSS)were decreased(P<0.05).Compared with the control group,the levels of SOD,VEGF,BDNF and other indicators in the observation group were higher after treatment.The levels of MMP-9,IL-6,FBG,2 h PG and HbA1c were lower.BI was higher,mRS and NIHSS were lower,the difference were statistically significant(P<0.05).The total effective rate in the observation group was 94.20%(65/69),higher than 84.06%(58/69)in the control group(P<0.05).Conclusion:For patients with acute cerebral infarction complicated with diabetes(type of qi deficiency and blood stasis),the combination of Jiedu Jiangtang Futan Decoction and acupuncture and moxi-bustion treatment is helpful to promote blood supply to the brain,correct the imbalance of oxidative stress,regulate blood sugar level and improve clinical efficacy.

Objective To explore the application value of Kaiqiao Xingshen acupuncture combined with Buyang Huanwu decoction in the treatment of patients with cerebral hemorrhage in the recovery period(Qi defi-ciency and blood stasis syndrome),and to observe its impact on inflammatory indicators and neurokines.Method A total of 166 patients with cerebral hemorrhage in the recovery period(Qi deficiency and blood stasis syndrome)treated in Hongdu Traditional Chinese Medicine Hospital from September 2021 to October 2023,were randomly divided into control group(83 cases treated with conventional western medicine),and observation group(83 cases treated with a combination of Kaiqiao Xingshen acupuncture and Buyang Huanwu decoction).The therapeutic effect in the two groups was compared after 8 weeks of treatment.Results After treatment,the serum levels of matrix metalloproteinase-9(MMP-9),endothelin-1(ET-1),interleukin-2(IL-2),homocysteine(Hcy),and Bcl-2-associated X protein(bax)decreased in both groups,while brain-derived neurotrophic factor(BDNF)increased,and the improvement was more significant in the observation group,showing statistical significance(P<0.05);the average cerebral vascular flow and flow velocity in the observation group increased,while peripheral vascular resistance decreased,and the improvement in the observation group was more significant(P<0.05);the total symptom score of traditional Chinese medicine in the observation group decreased,while the Fuel Meyer functional score(FMA score)increased,and the improvement in the observation group was more significant(P<0.05);The total effective rate of the observation group was 93.98%(78/83),which was higher than that of the control group(80.72%,67/83)(P<0.05).Conclusion For patients with cerebral hemorrhage in the recovery period(Qi deficiency and blood stasis syndrome),Kaiqiao Xingshen acupuncture and Buyang Huanwu decoction help alleviate inflammatory reactions,promote the recovery of the blood-brain barrier,improve cerebral blood flow,promote neurological function recovery,and enhance clinical efficacy.

Objective:To evaluate the efficacy and safety of nebulized inhalation of recombinant human interferon (IFN) α1b injection in the treatment of respiratory syncytial virus (RSV) associated lower respiratory tract infections (pneumonia and bronchiolitis) in children.Methods:A randomized, double-blind, parallel, placebo-controlled add-on design was used.Children with pneumonia or bronchiolitis aged 2 months to 5 years who tested positive for RSV antigen within 72 hours of onset from 30 clinical trial sites including Beijing Children′s Hospital, Capital Medical University between February 2021 and December 2022 were included in this study and randomly divided into 2 groups at a ratio of 1∶1 based on a stratified-block method.Both groups received basic treatments such as cough control, asthma relieving, expectorant treatment, fever reduction, oxygen therapy, etc.The experimental group received additional nebulized inhalation of IFN α1b injection at a dose of 2.0 μg/(kg·time), twice a day.The control group received nebulized inhalation of placebo twice a day.Clinical efficacy was evaluated based on indicators such as the duration of clinical symptoms and signs, and the Kaplan-Meier method was used to calculate the median and 95% CI of the duration of clinical symptoms and signs.The Log-rank test was used to compared data between groups.Safety was assessed through the incidence of adverse reactions and laboratory tests, and the Chi-square test was used to analyze the difference between groups. Results:There were 123 children in the experimental group and 122 children in the control group.The median durations of all the 5 clinical symptoms and signs [including shortness of breath, wheezing, dyspnea (visible retractions), decreased transcutaneous oxygen saturation, and abnormal mental state] in the experimental group after treatment were slightly shortened than those in the control group [2.7 d(95% CI: 1.9-3.0 d)] vs.[2.9 d(95% CI: 2.6-3.6 d), P=0.027].The improvement in dyspnea (retractions) was especially pronounced in the experimental group, with a relief rate of 50.0% (0, 100%) on the first day of administration[compared with 0 (0, 50.0%) in the control group ( Z=2.002, P=0.025)].The median duration of dyspnea in the experimental group was nearly 1 day shorter than that in the control group [1.0 d(95% CI: 0.7-1.7 d) vs.1.8 d(95% CI: 1.0-2.5 d), P=0.046].There were no significant difference in hospital stay [6.0(5.0, 8.0) d vs.6.5(5.0, 8.0) d, Z=0.675, P=0.500], oxygen therapy duration [32.0(14.0, 96.3) h vs.39.0 (24.0, 83.2) h, Z=0.094, P=0.925], the recovery rate from clinical symptoms during treatment [(105/106, 99.1%) vs.(96/101, 95.0%)], and recurrence rate [(0/106, 0) vs.(2/101, 2.0%)] between the 2 groups (all P>0.05).However, the above-mentioned four indicators in the experimental group showed a trend of clinical benefits.The quantitative virus detection results showed that the RSV viral load in both groups decreased after treatment compared to before treatment.After 2 days of treatment, the decline rate of RSV viral load from the baseline was 0.90 lg copies/(mL·d) in the experimental group and 0.25 lg copies/(mL·d)in the control group, with a statistically significant difference ( P<0.05).Furthermore, there was no statistically significant difference in the incidence of adverse reactions between the 2 groups ( P>0.05).Importantly, no drug-related serious adverse reactions occurred in both groups. Conclusions:The nebulized inhalation therapy of IFN α1b demonstrates efficacy and safety in treating pediatric RSV associated lower respiratory tract infections.It particularly offers outstanding clinical therapeutic value for severe children.

Objective:To explore stigma and related factors among family members of patients with mental disorders in psychiatric hospitals.Methods:Totally 1 365 family members of inpatients with mental disorders were-surveyed,and were assessed with the Perceived Devaluation-Discrimination Scale and a self-made demographic characteristics questionnaire.Results:The screening rate of stigma among the patient's family members was 61.5％.Males(OR=2.26,95％CI:1.06-5.01),age group of 18-29 years(OR=1.91,95％CI:1.15-3.20),monthly income ≥500 yuan(P＜0.05),disease duration of 0.5-＜lyear(OR=3.14,95％CI:1.66-6.03),care for patients within＜lyear(P＜0.05),teachers(OR=2.32,95％CI:1.24-3.44),self-employed person(OR=1.63,95％CI:1.02-2.24),civil servants(OR=1.77,95％CI:1.09-2.45),schizophrenia(OR=1.87,95％CI:1.32-2.42),affective disorders(OR=1.52,95％CI:1.03-2.016)were the main riskfactors of stigma.Conclusions:Family members of patients with mental disorders generally have a severe stigma,especially of patients with schizophrenia and affective disorders.

Objective:To discuss the effects of panax notoginseng saponins (PNS) enteric-coated pellets on hemorrheology in rabbits.Methods:The rabbits were divided into the normal control group,the model control group,Xueshuangtong injection (lyophilization) group(15 mg·kg-1·d-1 ,im),PNS enteric-coated pellets groups respectively at high(45 mg·kg-1·d-1,ig),medium(30 mg·kg-1·d-1,ig) and low (15 mg·kg-1·d-1,ig) dose.The model was established by intragastric administration of high-fat diet.The whole-blood viscosity,plasma viscosity,erythrocyte aggregational index,crythrocyte index of rigidity and erythrocyte electro-phoresis rate in the groups were detected using hemorheological methods.Results:The above indices of hemorheology in the model control group were all significantly higher than those in the normal control group (P<0.01),suggesting the successful establishment of the model.Compared with the model control group,PNS enteric-coated pellets at high and medium doses could significantly reduce the whole blood viscosity and plasma viscosity(P<0.01 or P<0.05);PNS enteric-coated pellets group at low dose could significantly reduce the whole blood middle shear viscosity and plasma viscosity(P<0.05);the three PNS enteric-coated pellets groups could significantly reduce the agglutination index(P<0.01);PNS enteric-coated pellets at high and medium doses could significantly reduce the crythrocyte index of rigidity(P<0.01 or P<0.05);the three PNS enteric-coated pellets groups could significantly reduce the erythrocyte electro-phoresis rate,while there was no significant difference(P>0.05).Compared with Xueshuangtong injection (lyophilization) group,PNS enteric-coated pellets group at medium dose could significantly reduce the whole blood middle shear viscosity(P<0.05).Conclusion:PNS enteric-coated pellets can reduce the whole-blood viscosity,plasma viscosity,erythrocyte aggregational index,crythrocyte index of rigidity and erythrocyte electro-phoresis rate,and effectively promote blood circulation and remove stasis,inhibit thrombosis formation and increase blood supply for heart and cerebral vessels.

OBJECTIVE:To optimize preparation formulation of Tetrandrine solid dispersion tablets. METHODS:Tetrandrine solid dispersion tablets were prepared by direct compression method. Excipients were screened with single factor test. Taking disinte-gration time as index,the formulation of Tetrandrine solid dispersion tablets was optimized by orthogonal design using the amount of PVPP,lactose-microcrystalline cellulose proportion and the amount of gum acacia as factors. The optimized formulation was vali-dated. Prepared tablets were compared with Tetrandrine common tablet in dissolution rate,and the contents of the tablets prepared by optimized formulation were also determined. RESULTS:Optimal formulation was as follows as 9.5% PVPP as disintegrating agent,lactose-microcrystalline cellulose(1∶2)as filler,mixing,1% aerosil as lubricant,direct compression. For 3 batches of tab-lets,disintegration time were 79,81 and 78 s;contents were 98.66%,99.24%,99.85%;RSDs were 0.72%,1.16%,1.33%,re-spectively. Combined with Tetrandrine common tablets,the dissolution rate of prepared tablets had been improved significantly. CONCLUSIONS:Tetrandrine solid dispersion tablets are prepared successfully with rational reproducible formulation.

Objective:To establish an HPLC method for the simultaneous determination of narirutin, limonin, honokiol and mag-nolol in Zhishi Xiaopi pills. Methods:The separation was performed on a Shim-pack VP-ODS C18(250 mm ×4.6 mm,5 μm)column with the mobile phase consisting of acetonitrile–methanol(1 ∶2) (A) and water (B) with gradient elution. The flow rate was 1. 0 ml ·min-1 . The column temperature was 30℃. All the injection volume was 20 μl. Narirutin, limonin, honokiol and magnolol was de-tected at 283 nm, 210 nm, 294 nm and 294 nm, respectively. Results:Narirutin, limonin, honokiol and magnolol had good linearity within the concentration range of 5. 26-105. 20 μg·ml-1(r=0. 999 8), 7. 65-153. 00 μg·ml-1(r=0. 999 4), 6. 21-124. 20 μg· ml-1(r=0.999 3)and 6.45-129.00 μg·ml-1(r=0.999 6), respectively; the average recovery was 99.00%(RSD=0.77%), 98. 17%(RSD=1. 19%), 98. 78%(RSD=0. 86%) and 97. 90%(RSD=0. 99%), respectively. Conclusion: The method is sim-ple, rapid and reliable, which can be used for the quality control of Zhishi Xiaopi pills.